Condition: Cardiomyopathies · Heart Failure · Sponsor: Zoll Medical Corporation
The primary objective of this pilot study is to document the percentage achievement in effective HR control (average nighttime HR \< 70 bpm) during WCD use in a cohort of female patients with cardiomyopathy in an outpatient setting using continuous heart rate (HR) trends data from the WCD to optimize BB/ivabradine dosage, as compared to a prior historical control.
This description comes directly from the study's public registry record.
Mike Osz · 412-968-3333 · mosz@zoll.com
Tara Roberts · 412-968-3333 · tara.roberts@zoll.com
Always discuss trial participation with your own doctor first.
| TriHealth Hatton Research Institute | Cincinnati, Ohio, United States | Recruiting |
| Texas Cardiology Associates of Houston | Kingwood, Texas, United States | Terminated |
| CardioVoyage | McKinney, Texas, United States | Recruiting |
| CAMC | Charleston, West Virginia, United States | Terminated |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04504188